Patients surviving longer than 2.5 years after isolated brain relapse
| Age, y/sex . | ECOG PS . | MTX . | MTX route . | WBRT . | Best response . | Progression site . | TTP, y . | Second-line treatment . | OS, y . | Cause of death . |
|---|---|---|---|---|---|---|---|---|---|---|
| 58/M | NR | Yes | IV | Yes | CR | CNS/Sys | 2.6 | CT | 10.8§ | — |
| 43/F | 4 | Yes | IV | Yes | CR | CNS | 5.8 | CT | 9.7 | CNS lymphoma |
| 55/F | NR | Yes* | IV, IT | Yes | CR | — | — | — | 9.1 | CNS toxicity |
| 35/M | NR | No | Yes | CR | — | — | — | 8.3§ | — | |
| 60/M | 1 | Yes* | IV | No | CR | CNS/Sys | 1.7 | CT | 7.4§ | — |
| 62/F | 2 | Yes | IV | Yes | CR | CNS | 4.0 | CT/RT | 7.0 | CNS lymphoma |
| 50/F | 2 | No† | — | No | CR | CNS | 3.5 | RT | 6.3 | CNS lymphoma |
| 48/M | 1 | Yes* | IA‡ | No | CR | Sys | 1.7 | CT | 6.1§ | — |
| 62/M | 0 | Yes* | IV‡ | No | CR | — | — | — | 5.7§ | — |
| 70/F | 2 | Yes | IV | Yes | NR | — | — | — | 5.6 | Unknown |
| 65/M | NR | Yes | IV | No | CR | CNS | 1.9 | CT | 5.5§ | — |
| 51/M | 2 | Yes | IT | Yes | CR | — | — | — | 5.1§ | — |
| 77/F | 3 | Yes | IV | No | CR | — | — | — | 4.9§ | — |
| 66/F | 3 | Yes | IV | No | CR | — | — | — | 4.8§ | — |
| 69/M | 3 | Yes | IV | Yes | CR | — | — | — | 4.7 | Unknown |
| 58/F | 2 | No | — | Yes | NR | Sys | 0.7 | NR | 4.6§ | — |
| 68/F | 3 | No | — | Yes | CR | — | — | — | 4.4 | CNS toxicity |
| 43/M | 2 | Yes | IV | No | PR | CNS | 0.7 | CT | 4.2§ | — |
| 80/M | NR | Yes | IV | No | CR | CNS | 3.3 | CT | 3.9 | Unknown |
| 19/M | NR | Yes | IV | Yes | CR | — | — | — | 3.9§ | — |
| 26/F | 1 | Yes | IV | Yes | CR | Sys | 0.4 | CT | 3.7§ | — |
| 60/F | 3 | Yes | IA‡ | No | CR | CNS | 1.8 | CT | 3.5 | CNS lymphoma |
| 70/F | 3 | No | — | Yes | CR | CNS | 3.3 | — | 3.4 | CNS lymphoma |
| 55/F | 2 | Yes | IV | No | CR | CNS | 2.0 | CT | 3.3 | Unknown |
| 44/F | 2 | Yes | IA‡ | No | CR | CNS | 2.7 | CT | 3.3 | CNS lymphoma |
| 70/F | 1 | No | — | Yes | CR | — | — | — | 3.1§ | — |
| 51/F | 1 | Yes | IV | Yes | CR | CNS | 2.5 | CT | 2.9 | CNS lymphoma |
| 42/F | 3 | Yes* | IV | No | CR | Sys | 0.8 | CT | 2.8 | CNS lymphoma |
| 49/M | 2 | Yes | IA‡ | No | CR | CNS | 1.2 | CT/RT | 2.6 | CNS/Sys lymphoma |
| 78/F | 3 | No | — | Yes | NR | Sys | 0.9 | RT | 2.6 | CNS lymphoma |
| 60/M | NR | Yes | IV | No | CR | CNS | 2.5 | RT | 2.6 | CNS lymphoma |
| Age, y/sex . | ECOG PS . | MTX . | MTX route . | WBRT . | Best response . | Progression site . | TTP, y . | Second-line treatment . | OS, y . | Cause of death . |
|---|---|---|---|---|---|---|---|---|---|---|
| 58/M | NR | Yes | IV | Yes | CR | CNS/Sys | 2.6 | CT | 10.8§ | — |
| 43/F | 4 | Yes | IV | Yes | CR | CNS | 5.8 | CT | 9.7 | CNS lymphoma |
| 55/F | NR | Yes* | IV, IT | Yes | CR | — | — | — | 9.1 | CNS toxicity |
| 35/M | NR | No | Yes | CR | — | — | — | 8.3§ | — | |
| 60/M | 1 | Yes* | IV | No | CR | CNS/Sys | 1.7 | CT | 7.4§ | — |
| 62/F | 2 | Yes | IV | Yes | CR | CNS | 4.0 | CT/RT | 7.0 | CNS lymphoma |
| 50/F | 2 | No† | — | No | CR | CNS | 3.5 | RT | 6.3 | CNS lymphoma |
| 48/M | 1 | Yes* | IA‡ | No | CR | Sys | 1.7 | CT | 6.1§ | — |
| 62/M | 0 | Yes* | IV‡ | No | CR | — | — | — | 5.7§ | — |
| 70/F | 2 | Yes | IV | Yes | NR | — | — | — | 5.6 | Unknown |
| 65/M | NR | Yes | IV | No | CR | CNS | 1.9 | CT | 5.5§ | — |
| 51/M | 2 | Yes | IT | Yes | CR | — | — | — | 5.1§ | — |
| 77/F | 3 | Yes | IV | No | CR | — | — | — | 4.9§ | — |
| 66/F | 3 | Yes | IV | No | CR | — | — | — | 4.8§ | — |
| 69/M | 3 | Yes | IV | Yes | CR | — | — | — | 4.7 | Unknown |
| 58/F | 2 | No | — | Yes | NR | Sys | 0.7 | NR | 4.6§ | — |
| 68/F | 3 | No | — | Yes | CR | — | — | — | 4.4 | CNS toxicity |
| 43/M | 2 | Yes | IV | No | PR | CNS | 0.7 | CT | 4.2§ | — |
| 80/M | NR | Yes | IV | No | CR | CNS | 3.3 | CT | 3.9 | Unknown |
| 19/M | NR | Yes | IV | Yes | CR | — | — | — | 3.9§ | — |
| 26/F | 1 | Yes | IV | Yes | CR | Sys | 0.4 | CT | 3.7§ | — |
| 60/F | 3 | Yes | IA‡ | No | CR | CNS | 1.8 | CT | 3.5 | CNS lymphoma |
| 70/F | 3 | No | — | Yes | CR | CNS | 3.3 | — | 3.4 | CNS lymphoma |
| 55/F | 2 | Yes | IV | No | CR | CNS | 2.0 | CT | 3.3 | Unknown |
| 44/F | 2 | Yes | IA‡ | No | CR | CNS | 2.7 | CT | 3.3 | CNS lymphoma |
| 70/F | 1 | No | — | Yes | CR | — | — | — | 3.1§ | — |
| 51/F | 1 | Yes | IV | Yes | CR | CNS | 2.5 | CT | 2.9 | CNS lymphoma |
| 42/F | 3 | Yes* | IV | No | CR | Sys | 0.8 | CT | 2.8 | CNS lymphoma |
| 49/M | 2 | Yes | IA‡ | No | CR | CNS | 1.2 | CT/RT | 2.6 | CNS/Sys lymphoma |
| 78/F | 3 | No | — | Yes | NR | Sys | 0.9 | RT | 2.6 | CNS lymphoma |
| 60/M | NR | Yes | IV | No | CR | CNS | 2.5 | RT | 2.6 | CNS lymphoma |
MTX indicates methotrexate; WBRT, whole brain radiotherapy; TTP, time to progression; OS, overall survival; NR, not reported; IV, intravenous; CR, complete response; Sys, systemic; CT, chemotherapy; IT, intrathecal; RT, radiotherapy; IA, intraarterial; PR, partial response; and —, not applicable.
After treatment with MTX, patient received high-dose chemotherapy with peripheral blood stem cell or marrow transplantation.
Patient received bleomycin, vincristine, procarbazine, prednisone, dexamethasone, ifosfamide, carboplatin, and etoposide.
Patient received MTX in conjunction with osmotic blood-brain barrier disruption.
Alive at time of data cutoff.